Evidence map›Paper›PMID 38630010›Full record

Observational studyThe Journal of clinical endocrinology and metabolism2024

Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan.

Soji Toda, Yukihiko Hiroshima, Hiroyuki Iwasaki, Katsuhiko Masudo

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Soji TodaDepartment of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.ORCID 0000-0002-2977-4419
Yukihiko HiroshimaDepartment of Cancer Genome Medicine, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.
Hiroyuki IwasakiDepartment of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.ORCID 0000-0002-9724-8525
Katsuhiko MasudoDepartment of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.
Kanagawa Prefectural Hospital Organization · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextThe relationship between the genomic profile and prognosis of advanced thyroid carcinoma requiring drug therapy has not been reported.

objectiveTo evaluate the treatment period and overall survival time for each genetic alteration in advanced thyroid carcinoma that requires drug therapy.

methodsWe conducted a retrospective observational study using a national database in Japan, which included 552 cases of thyroid carcinoma out of 53 543 patients in the database.

resultsThe database included anaplastic thyroid carcinoma (23.6%), poorly differentiated thyroid carcinoma (10.0%), and differentiated thyroid carcinoma (66.4%). The most common genetic abnormalities were TERT promoter (66.3%), BRAF (56.7%), and TP53 (32.2%). The typical driver genes were BRAF V600E (55.0%), RAS (18.5%), RET fusion (4.7%), NTRK fusion (1.6%), and ALK fusion (0.4%). The most common regimen was lenvatinib, and the time to treatment failure was not different despite the presence of BRAF or RAS mutations. In differentiated thyroid carcinoma and poorly differentiated thyroid carcinoma, TP53 alterations independently predicted worse overall survival (hazard ratio = 2.205, 95% confidence interval: 1.135-4.283). In anaplastic thyroid carcinoma, no genetic alterations were associated with overall survival.

conclusionGenetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.

Indexed as

Databases, FactualPhenylurea CompoundsThyroid NeoplasmsAdultAgedAged, 80 and overAntineoplastic AgentsFemaleGenomicsHumansJapanMaleMiddle AgedMutationPrognosisProto-Oncogene Proteins B-rafAntineoplastic AgentsBRAF protein, humanlenvatinibPhenylurea CompoundsProto-Oncogene Proteins B-rafQuinolinesTelomeraseTERT protein, humanTP53 protein, humanTumor Suppressor Protein p53comprehensive genetic profiling testfusionsgenemutationstargeted therapythyroid carcinoma

Identifiers

PMID38630010
PMCPMC11479701
OpenAlexW4394869058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.